Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Coenzyme I injection for prevention of cancer therapy-related cardiac dysfunction and neutropenia
ChiCTR2600131978Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nicotinamide adenine dinucleotide in chemotherapy-induced cardiotoxicity (CIC) and neutropenia, sponsored by Zhejiang Cancer Hospital. Primary endpoint: 12-month incidence of cancer therapy-related cardiac dysfunction. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
chemotherapy-induced cardiotoxicity (CIC)neutropenia
Beyond the preview
Go deeper on ChiCTR2600131978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131978.